Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for the treatment of substance abuse and dependence

An anxiety disorder, an effective amount of technology, a method and composition applied in the field of symptoms, treatment, diagnosis of people with altered GABAA receptor status, a class of compounds that modulate the expression of certain GABAA receptor subunits, and capable of addressing enhanced Stress withdrawal symptoms, failure, etc.

Inactive Publication Date: 2008-09-24
HYTHIAM
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Drug therapy is sometimes unfavorable because the patient will respond to the drug of choice such as benzodiazepines Dependence on serotonin-like or selective serotonin reuptake inhibitors, which enhances stress-related withdrawal symptoms
At the same time, conventional therapeutic approaches fail when they do not produce the physiochemical changes that co-occur with anxiety-related disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the treatment of substance abuse and dependence
  • Methods for the treatment of substance abuse and dependence
  • Methods for the treatment of substance abuse and dependence

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0238] VII. Example 1: Scheme for the treatment of general anxiety disorders

[0239] Anxiety disorders are usually debilitating and chronic diseases that worsen under stress and are related to changes in hormone levels in the body. To compensate for this hormonal change or to increase progesterone as described above, people try to produce greater stress in their lives. GABA-regulating steroids such as progesterone and its metabolite allopregnanolone act on GABA receptor function, therefore, when progesterone is down-regulated in an individual (for example, in the case of certain anxiety disorders), GABAA receptor alpha 4 Subunit expression relative to α 1 The expression of subunits is increased. By restoring GABAA to the normal level of receptor subunits (decreasing alpha 4 And increase the amount of α 1 Amount, for GABA and benzodiazepine The combination of classes is more sensitive), which can treat underlying disease states.

[0240] a. Pre-treatment / patient evaluation stage ...

Embodiment 2

[0270]Male, 30 years old, diagnosed with general anxiety disorder under DSM IV criteria. He is currently undergoing medication, including 20 mg / day paroxetine and 0.25 mg / day alprazolam (maximum 4 mg in 24 hours) as needed.

[0271] Patient preparation step 1: 6 weeks before the scheduled treatment, instruct the patient to reduce the dose of paroxetine to 10 mg / day in 2 weeks. Four weeks before the scheduled treatment, the patient was instructed to stop all drugs, including alprazolam and paroxetine.

[0272] Patient preparation step 2: 4 weeks before the scheduled treatment, he started to administer 5 mg / day finasteride as scheduled. Three days before the scheduled treatment, finasteride was stopped and the patient was instructed not to engage in any stress-inducing activities or ingest any substances that might increase the production of neurosteroids.

[0273] Treatment on Day 1: The male patient was administered flumazenil by infusion in an amount of less than 15 mg / day. Monit...

Embodiment 3

[0320] IX. Example 3: Treatment plan for specific phobia and social phobia (social anxiety disorder)

[0321] Terror is a strong, irrational fear that avoids objects and environments. The person knows that this fear is irrational and remains anxious. Phobia is different from general anxiety disorder and panic disorder because there are specific stimuli or situations that trigger a strong fear response.

[0322] a. Pre-treatment / patient evaluation stage

[0323] As mentioned above, before entering the treatment plan of the present invention, each patient should undergo pre-treatment analysis. Pre-treatment analysis can be used to determine whether the patient is the best candidate for the treatment method of the present invention. In addition, the pre-treatment process can be used to prepare the patient to enter the treatment method of the present invention.

[0324] i. Diagnosis of specific horror

[0325] ■Because of the existence or anticipation of specific objects or situations,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to treat anxiety-related disorders and depressive disorders associated with physiological tolerance to endogenous neurosteroids.

Description

[0001] Cross reference with related applications [0002] The present invention requires U.S. Provisional Patent Application No. 60 / 669,033, filed on April 7, 2005, entitled "Improved Methods of Treating Substance Abuse", and filed on October 21, 2005, entitled "Methods of Treating Substance Abuse and Dependence" Priority of the US Provisional Patent Application No. 60 / 728,979, and the US Provisional Patent Application No. 60 / 729,013 filed on October 21, 2005, entitled “Methods for Treating Anxiety Related Disorders”. Invention field [0003] The present invention relates to methods and compositions for treating and alleviating symptoms and diseases related to indications caused by the physiological drive to cope with anxiety. More specifically, the present invention relates to methods and compositions for treating and alleviating symptoms associated with endogenous neurosteroid withdrawal. [0004] The invention also relates to diagnosing GABA A The method of a person whose recipi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01N33/02A01N43/42A61K31/135A61K31/44
Inventor S·萨布纳尼D·韦森
Owner HYTHIAM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com